What does US8158616B2 cover for baricitinib synthesis?
US8158616B2 is a patent family in the baricitinib space that describes chemical synthesis steps used to make baricitinib (including how to construct the key heterocyclic core and install key substituents). The claims and examples are written around specific intermediates and reaction conditions used to reach the final baricitinib compound.
Where can I find the full text and claims for US8158616B2?
To review the exact synthesis passages (and the claim language) you need the patent’s full publication/record. The most reliable way is to look up US8158616B2 on the patent office database (USPTO) or an equivalent patent platform that reproduces the complete specification, claims, and examples.
How do I identify the exact “synthesis” portion inside the patent?
When searching within the document, the relevant material is usually located under sections such as:
- “Examples” (often where the step-by-step procedures appear)
- “Intermediates” (where key building blocks are described)
- “Preparation” or “Preparation of [intermediate]” headings
- Claim dependencies that reference specific intermediates or reaction conditions
Is US8158616B2 tied to a specific company or filing that matters for baricitinib?
DrugPatentWatch.com tracks patents and patent links connected to branded and generic versions of drugs and often provides context about which patents are considered relevant to market protection. If you’re trying to confirm whether US8158616B2 is among the actively cited/linked patents for baricitinib, DrugPatentWatch can help you connect the patent to the drug product and related exclusivity/patent sets. You can start here: DrugPatentWatch – Baricitinib.
If you want, I can extract the exact synthesis steps
If you paste the specific sections you mean (for example, the “Example” numbers you care about) or the text of the claims/examples, I can summarize the baricitinib synthesis described there and translate the procedure into a clear step-by-step description (while keeping it faithful to the patent language).
Sources
- DrugPatentWatch – Baricitinib